1-3 of 3
Federico Simonetta, MDPhD
Close
Sort by
Journal Articles

Real-Life Experience of Sorafenib Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML Reveals High Rates of Toxicity-Related Treatment Interruption

Sarah Morin, MD PhD, Federica Giannotti, MD, Anne-Claire Mamez, MD, Stavroula Masouridi-Levrat, MD, Federico Simonetta, MDPhD, Yves Chalandon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-138663
Published: 2020
Journal Articles

Impact of Different T Cell Depletion Protocols on Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation

Amandine Pradier, PhD, Adrien Petitpas, Anne-Claire Mamez, MD, Federica Giannotti, MD, Sarah Morin, MD PhD, Elif Mahne, MD, Yan Beauverd, MD, Mitja Nabergoj, Carmen De Ramon Ortiz, MD, Maria Anastasiou, MD, Maria Mappoura, MD, Thien-An Tran, MD, Christian Ayer, MD, Anna Petropoulou, MD, Benjamin Bruno, MD, Paraskevi Stakia, MD, Laura Bounaix, MD, Stavroula Masouridi-Levrat, MD, Federico Simonetta, MDPhD, Yves Chalandon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-139208
Published: 2020
Journal Articles

The AML EBMT Cytogenetic Risk Score for Acute Myeloid Leukaemia (AML) Is Prognostic for Outcomes of Allogeneic Stem Cell (HSCT)

Yan Beauverd, MD, Sarah Morin, MD PhD, Mitja Nabergoj, Caroline Stephan, Carmen De Ramon Ortiz, MD, Anne-Claire Mamez, MD, Elif Mahne, MD, Anna Petropoulou, MD, Federica Giannotti, MD, Federico Simonetta, MDPhD, Christian Ayer, MD, Benjamin Bruno, MD, Laura Bounaix, MD, Maria Anastasiou, MD, Maria Mappoura, MD, Thien-An Tran, MD, Stavroula Masouridi-Levrat, MD, Yves Chalandon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-140010
Published: 2020